thalidomide has been researched along with Histiocytic Sarcoma in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Histiocytic Sarcoma: Malignant neoplasms composed of MACROPHAGES or DENDRITIC CELLS. Most histiocytic sarcomas present as localized tumor masses without a leukemic phase. Though the biological behavior of these neoplasms resemble lymphomas, their cell lineage is histiocytic not lymphoid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation--metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma--in pediatric patients." | 3.78 | Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. ( Bailey, KM; Castle, VP; Hummel, JM; McAllister-Lucas, LM; Moyer, J; Piert, M, 2012) |
| "Mediastinal nonseminomatous germ cell tumor (MNSGCT)-associated histiocytic proliferations are rare and rapidly fatal disorders." | 1.43 | Mediastinal Germ Cell Tumor-associated Histiocytic Proliferations Treated With Thalidomide Plus Chemotherapy Followed by Alemtuzumab-containing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report. ( Chen, RL; Chen, WT; Fang, LH; Lee, PI; Shih, LS, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, LH | 1 |
| Shih, LS | 1 |
| Lee, PI | 1 |
| Chen, WT | 1 |
| Chen, RL | 1 |
| Gergis, U | 1 |
| Dax, H | 1 |
| Ritchie, E | 1 |
| Marcus, R | 1 |
| Wissa, U | 1 |
| Orazi, A | 1 |
| Shukla, N | 1 |
| Kobos, R | 1 |
| Renaud, T | 1 |
| Teruya-Feldstein, J | 1 |
| Price, A | 1 |
| McAllister-Lucas, L | 1 |
| Steinherz, P | 1 |
| Bailey, KM | 1 |
| Castle, VP | 1 |
| Hummel, JM | 1 |
| Piert, M | 1 |
| Moyer, J | 1 |
| McAllister-Lucas, LM | 1 |
1 review available for thalidomide and Histiocytic Sarcoma
| Article | Year |
|---|---|
Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Hematopoietic Stem Cell Transplantation; Hist | 2011 |
3 other studies available for thalidomide and Histiocytic Sarcoma
| Article | Year |
|---|---|
Mediastinal Germ Cell Tumor-associated Histiocytic Proliferations Treated With Thalidomide Plus Chemotherapy Followed by Alemtuzumab-containing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Fatal Outcome; Histiocytic Sa | 2016 |
Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, | 2012 |
Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.
Topics: Adolescent; Child; Female; Histiocytic Sarcoma; Humans; Immunosuppressive Agents; Michigan; Precurso | 2012 |